The IMA Group (IMA) has acquired multi-therapeutic company Clinical Trials of America (CTA) in the US.

This acquisition will bring four new independent locations and six embedded sites in Louisiana and North Carolina to IMA.

CTA’s existing leadership, investigators, and staff will remain in place, led by its former CEO and president Jeb Andrews, and the company will continue its operations.

The IMA Group president and CEO Dr Mark Weinberger said: “The addition of CTA is a natural fit for our organisation, expanding our clinical network and adding a large, scalable research business that further differentiates us to sponsors and contract research organisations (CRO) for fast startup, quick enrolment, and high-quality outcomes.

“Our clinical research division has grown more than 300% during the past three years. CTA’s integrated physician practice research model and focus on recruiting diverse patients ideally fits with IMA Clinical Research’s vision and growth trajectory.”

CTA has therapeutic expertise in gastroenterology, cardiology, dermatology, vaccines, family medicine, and psychiatry.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With this expertise of the company, the transaction further extends IMA Clinical Research’s reach in the Southeast.

The transaction also delivers productivity platforms, enabled by the technology and central services model of IMA, to more physicians’ offices.

New research capabilities of the company will also help expedite startup and the recruitment of participants while providing a wide range of trial opportunities to more patients.

Patients will get trial opportunities for additional disease states including hypertension, nonalcoholic steatohepatitis (NASH), atrial fibrillation, asthma, and smoking cessation.

Joining the IMA Clinical Research team as Operations senior regional director, Andrews will continue to lead the CTA sites and serve as a sub-investigator.

For this division, he will also assist with the development of new study sites and principal investigator onboarding.

The companies have not disclosed the terms of the transaction.